Olpha Competitors and Similar CompaniesClear all
Oxurion's competitors and similar companies include Aerie Pharmaceuticals.
 Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. | |
Founding Date | Founding Date 1991 | Founding Date 2005 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Leuven, BE HQ Dublin 8, IE | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US |
Employees | Employees 785% increase | Employees 3808% increase |
Valuation ($) | Valuation ($) 626.1 k | Valuation ($) 722.2 m |
Financial | ||
Revenue (est.) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $194.1m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) |
Net income | Net income (€3.7m) (FY, 2025) | Net income ($74.8m) (FY, 2021) |
Funding | ||
Total funding raised | Total funding raised $ 3.9m | Total funding raised $ 388.6m |
For sources of this data, please see the company profile
View Company Profiles
Aerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company